American scientists are raising a red warning flag over proposed studies of the drug minocycline for several neurodegenerative conditions. Reporting in Lancet Neurology, the researchers say that patients taking the off-patent minocycline for Lou Gehrig's disease declined more rapidly than the control group taking a placebo. That report comes as Canada's MS Society is funding a Phase III trial to determine if the drug can work to slow MS if it is administered during the early stage of the disease.
- check out the report [1] from the Canadian Press
Related Articles:
Antibody stimulates natural repair of MS damage. Report [2]
Natural protein used to combat multiple sclerosis. Report [3]
Links:
[1] http://canadianpress.google.com/article/ALeqM5hQmVL8rejKBsDVyES2nh2l7sX-5g
[2] http://www.fiercebioresearcher.com/story/antibody-stimulates-natural-repair-ms-damage/2007-10-16
[3] http://www.fiercebioresearcher.com/story/natural-protein-used-to-combat-multiple-sclerosis/2007-06-19